Rohr Ulrich-Peter, Wulf Marc-Andre, Stahn Susanne, Steidl Ulrich, Haas Rainer, Kronenwett Ralf
Klinik für Hämatologie, Onkologie und klinische Immunologie, Heinrich-Heine-Universität Düsseldorf, Moorenstrasse 5, D-40225, Düsseldorf, Germany.
J Virol Methods. 2002 Oct;106(1):81-8. doi: 10.1016/s0166-0934(02)00138-6.
In this study, a quantitative real-time PCR (qPCR) was developed to determine genomic rAAV-2 titers using the Light-Cycler technology. Since the CMV promoter is the most commonly used promoter in gene therapeutic approaches, primers were designed which hybridize with the human CMV promoter sequence. PCR products were detected by the addition of SYBR green. qPCR of a 5 log spanning serial dilution of the vector plasmid containing one CMV promoter per plasmid molecule yielded a high amplification efficiency of 1.99 per cycle. To quantify the copy number of viral genomes, the qPCR curves of adeno-associated virus type 2 (AAV-2) samples were related to a standard curve assessed by the 5 log spanning serial vector plasmid dilution (0.01-100 pg DNA). For validation of the method, rAAV-2 preparations were analyzed by a standard method and qPCR in parallel. As standard method, flow cytometry was used for titration of infectious viral particles on HeLa cells using the Enhanced Green Fluorescent Protein as a marker. A significant correlation was found between the results obtained by flow cytometry and the results from the qPCR over a 5 log range (r=0.85, P<0.0001). The mean ratio between infectious rAAV-2 particles titrated via flow cytometry and genomic copies of rAAV-2 measured by qPCR of the same sample was 1:253. The higher titers found by qPCR might be due to multiple transduction of a single cell or to non-infectious particles generated during rAAV-2 preparation. In conclusion, qPCR is a fast and reliable method for determination of rAAV-2 titers and might be a powerful tool for standardization of rAAV-2 preparations particularly in the context of clinical studies.
在本研究中,开发了一种定量实时聚合酶链反应(qPCR),以使用Light-Cycler技术测定基因组rAAV-2滴度。由于巨细胞病毒(CMV)启动子是基因治疗方法中最常用的启动子,因此设计了与人类CMV启动子序列杂交的引物。通过添加SYBR green检测PCR产物。对每个质粒分子含有一个CMV启动子的载体质粒进行5个对数跨度的系列稀释后的qPCR,每个循环产生1.99的高扩增效率。为了定量病毒基因组的拷贝数,将2型腺相关病毒(AAV-2)样品的qPCR曲线与通过5个对数跨度的系列载体质粒稀释(0.01 - 100 pg DNA)评估的标准曲线相关联。为了验证该方法,对rAAV-2制剂同时采用标准方法和qPCR进行分析。作为标准方法,使用增强型绿色荧光蛋白作为标记,通过流式细胞术对HeLa细胞上的感染性病毒颗粒进行滴定。在5个对数范围内,流式细胞术获得的结果与qPCR的结果之间发现了显著相关性(r = 0.85,P < 0.0001)。通过流式细胞术滴定的感染性rAAV-2颗粒与通过相同样品的qPCR测量的rAAV-2基因组拷贝数之间的平均比率为1:253。qPCR发现的较高滴度可能是由于单个细胞的多次转导或rAAV-2制备过程中产生的非感染性颗粒。总之,qPCR是一种快速可靠的测定rAAV-2滴度的方法,可能是rAAV-2制剂标准化的有力工具,特别是在临床研究背景下。